{"transactions":[{"id":822841,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-01T21:19:11.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date."}],"balance_after":105000,"derivative":{"exercise_price":2.49,"expiration_date":"2036-04-01","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001683168-26-002580","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826002580/ownership.xml","form_type":"4"}},{"id":1183402,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-02T17:41:10.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":41899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter."}],"balance_after":41899,"derivative":{"exercise_price":6.7,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":41899},"source":{"system":"sec-edgar","filing":"0001683168-25-002208","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825002208/ownership.xml","form_type":"4"}},{"id":1183401,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-02T17:41:10.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":49394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date."}],"balance_after":49394,"derivative":{"exercise_price":6.7,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":49394},"source":{"system":"sec-edgar","filing":"0001683168-25-002208","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825002208/ownership.xml","form_type":"4"}},{"id":1433612,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Options","published_at":"2024-08-14T23:28:37.000Z","date":"2024-08-14","kind":"grant","planned":false,"acquired":true,"shares":234971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"234,971 stock options granted upon the closing of the issuer's initial public offering on August 14, 2024, 25% of which vest on June 1, 2025 and the remaining 75% of which vest in equal monthly installments during the 36 months following June 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":8,"expiration_date":"2034-08-14","underlying":"Common Stock","underlying_shares":234971},"source":{"system":"sec-edgar","filing":"0001104659-24-089794","document":"tm2421559-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924089794/tm2421559-4_4seq1.xml","form_type":"4"}},{"id":2891259,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2021-01-29T22:32:17.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":161000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1641252},"source":{"system":"sec-edgar","filing":"0001683168-21-000322","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000322/ownership.xml","form_type":"4"}},{"id":2891258,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-29T22:32:17.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":1641252,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."}],"balance_after":1641252,"source":{"system":"sec-edgar","filing":"0001683168-21-000322","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000322/ownership.xml","form_type":"4"}},{"id":2943536,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-12-17T01:18:26.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":37772,"price":3.3,"value":124647.6,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan as a long-term incentive grant equal to 25% of reporting person's annual base salary. RSUs will vest 100% on August 31, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":80164,"derivative":{"exercise_date":"2022-08-31","underlying":"Common Stock","underlying_shares":37772},"source":{"system":"sec-edgar","filing":"0001683168-20-004324","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316820004324/ownership.xml","form_type":"4"}},{"id":2943535,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-12-17T01:18:26.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":42392,"price":3.3,"value":139893.6,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSU's granted under the Mosaic ImmunoEngineering Inc. 2020 Omnibus Incentive Plan as part of the reporting person's annual base salary. RSUs will vest 100% on August 31, 2021, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":42392,"derivative":{"exercise_date":"2021-08-31","underlying":"Common Stock","underlying_shares":42392},"source":{"system":"sec-edgar","filing":"0001683168-20-004324","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316820004324/ownership.xml","form_type":"4"}},{"id":4342738,"issuer":{"id":83494,"kind":"organization","name":"Avid Bioservices, Inc.","symbol":"CDMO"},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-04-28T18:57:34.000Z","date":"2017-04-28","kind":"other","acquired":true,"shares":37389,"price":0.2712,"value":10139.8968,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the issuer's employee stock purchase plan on April 28, 2017"}],"balance_after":184038,"source":{"system":"sec-edgar","filing":"0001683168-17-001049","document":"lytle_f4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/704562/000168316817001049/lytle_f4.xml","form_type":"4"}},{"id":4571435,"issuer":{"id":83494,"kind":"organization","name":"Avid Bioservices, Inc.","symbol":"CDMO"},"owners":[{"id":54675,"kind":"person","name":"LYTLE PAUL J","position":1,"cik":"0001244110","reported_name":"LYTLE PAUL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-11-01T20:04:02.000Z","date":"2016-10-31","kind":"other","acquired":true,"shares":33783,"price":0.2864,"value":9675.4512,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the issuer's employee stock purchase plan on October 31, 2016."}],"balance_after":146649,"source":{"system":"sec-edgar","filing":"0001683168-16-000447","document":"lytle_f4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/704562/000168316816000447/lytle_f4.xml","form_type":"4"}}]}